Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-A2 -Glycoprotein Levels in Patients with Type 2 Diabetes

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Liao, Xin ^a   Wang, Xuemei ^a   Li, Haopeng ^a   Li, Ling ^b   Zhang, Guohao ^a,c   Yang, Mengliu ^b   Yuan, Lei ^b   Liu, Hua ^d   Yang, Gangyi ^a   Gao, Lin ^a  

^a ZUNYI MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c Staff Hospital of Guizhou Maotal Mistillery Group Company   (China)

^d UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZGP1 PROTEIN, HUMAN; CARRIER PROTEIN; GLYCOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECRETION (PROCESS);

ADULT; CARRIER PROTEINS; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HUMANS; LIVER; MALE; MIDDLE AGED; PPAR GAMMA; PROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84986918002     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep32887     Document Type: Article

References (39)

1. Tada, T. et al. Immunohistochemical localization of Zn-alpha 2-glycoprotein in normal human tissues. J Histochem Cytochem 39, 1221-1226 (1991).
2. Burgi, W. & Schmid, K. Preparation and properties of Zn-alpha 2-glycoprotein of normal human plasma. J Biol Chem 236, 1066-1074 (1961).
3. Bing, C. et al. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci USA 101, 2500-2505 (2004).
4. Rolli, V. et al. Lipolysis is altered in MHC class I zinc-alpha(2)-glycoprotein deficient mice. FEBS Lett 581, 394-400 (2007).
5. Balaz, M. et al. Subcutaneous adipose tissue zinc-alpha2-glycoprotein is associated with adipose tissue and whole-body insulin sensitivity. Obesity (Silver Spring) 22, 1821-1829 (2014).
6. Yang, M. et al. Zinc-alpha2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes. Diabetes Care 36, 1074-1082 (2013).
7. List, J. F. & Whaley, J. M. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int Suppl, S20-S27 (2011).
8. Santer, R. et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14, 2873-2882 (2003).
9. Wright, E. M., Hirayama, B. A. & Loo, D. F. Active sugar transport in health and disease. J Intern Med 261, 32-43 (2007).
10. Kanai, Y., Lee, W. S., You, G., Brown, D. & Hediger, M. A. The human kidney low affinity Na+ /glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93, 397-404 (1994).
11. Hediger, M. A. & Rhoads, D. B. Molecular physiology of sodium-glucose cotransporters. Physiol Rev 74, 993-1026 (1994).
12. Idris I Fau-Donnelly, R. & Donnelly, R. Sodium-glucose co-transporter-2 inhibitors: An emerging new class of oral antidiabetic drug. Diabetes Obes Metab 11, 79-88 (2009).
13. Komoroski, B. et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 85, 513-519 (2009).
14. List, J. F., Woo, V., Morales, E., Tang, W. & Fiedorek, F. T. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32, 650-657 (2009).
15. Henry, R. R. et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 66, 446-456 (2012).
16. Fonseca, V. A. et al. Active-and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications 27, 268-273 (2013).
17. Hayashizaki-Someya, Y. et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol 754, 19-24 (2015).
18. Bradford, B. J. & Allen, M. S. Phlorizin induces lipolysis and alters meal patterns in both early-and late-lactation dairy cows. J Dairy Sci 90, 1810-1815 (2007).
19. Devenney, J. et al. The effect of dapagliflozin, a highly selective SGLT2 inhibitor, on body weight in diet-induced obese rats. Presented at The Obesity Society Annual Scientific Meeting 2007; Abstract 0384, New Orleans, LA (2007).
20. Zhu, H. J. et al. Inhibition of preadipocyte differentiation and adipogenesis by zinc-alpha2-glycoprotein treatment in 3T3-L1 cells. J Diabetes Investig 4, 252-260 (2013).
21. Goring, S. et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: A systematic review and network meta-analysis. Diabetes Obes Metab 16, 433-442 (2014).
22. Weyer, C. et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86, 1930-1935 (2001).
23. Tschritter, O. et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52, 239-243 (2003).
24. Matsubara, M., Maruoka, S. & Katayose, S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 87, 2764-2769 (2002).
25. Chen, L., Klein, T. & Leung, P. S. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice. Curr Mol Med 12, 995-1004 (2012).
26. Garrido-Sanchez, L. et al. Zinc-alpha 2-glycoprotein gene expression in adipose tissue is related with insulin resistance and lipolytic genes in morbidly obese patients. PLoS One 7, e33264 (2012).
27. Bao, Y. et al. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett 579, 41-47 (2005).
28. Russell, S. T. & Tisdale, M. J. Antidiabetic properties of zinc-alpha2-glycoprotein in ob/ob mice. Endocrinology 151, 948-957 (2010).
29. Mracek, T. et al. The adipokine zinc-alpha2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. Clin Endocrinol (Oxf) 72, 334-341 (2010).
30. Wargent, E. T. et al. Contrasts between the effects of zinc-alpha2-glycoprotein, a putative beta 3/2-adrenoceptor agonist and the beta3/2-adrenoceptor agonist BRL35135 in C57Bl/6 (ob/ob) mice. J Endocrinol 216, 157-168 (2013).
31. Russell, S. T. & Tisdale, M. J. Studies on the antiobesity effect of zinc-alpha2-glycoprotein in the ob/ob mouse. Int J Obes (Lond) 35, 345-354 (2011).
32. Shojima, N. et al. Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 51, 1737-1744 (2002).
33. Maeda, N. et al. PPAR? ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50, 2094-2099 (2001).
34. Bing, C. et al. Zinc-? 2-glycoprotein: An adipokine modulator of body fat mass? Int J Obes (Lond) 34, 1559-1565 (2010).
35. Alberti, K. G. & Zimmet, P. Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15, 539-553 (1998).
36. Albareda, M., Rodriguez-Espinosa, J., Murugo, M., de Leiva, A. & Corcoy, R. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 43, 1507-1511 (2000).
37. Hu, W. et al. Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. J Clin Endocrinol Metab 98, 290-298 (2013).
38. Li, K. et al. The effects of fibroblast growth factor-21 knockdown and over-expression on its signaling pathway and glucose-lipid metabolism in vitro. Mol Cell Endocrinol 348, 21-26 (2012).
39. Li, K. et al. Effect of short hairpin RNA-mediated adiponectin/Acrp30 down-regulation on insulin signaling and glucose uptake in the 3T3-L1 adipocytes. J Endocrinol Invest 33, 96-102 (2010).